BI 3000202 for Liver Disease

This trial aims to understand how the body processes a medicine called BI 3000202, a new potential drug, in people with and without liver problems. Participants will take one tablet of BI 3000202, and those with liver issues can continue their regular treatment. This study is best suited for adults who have had liver problems for some time, especially if they manage conditions like fluid buildup or high blood pressure in the liver with medication. Participants will visit the study site about 11 times over a month, with some visits possibly happening by phone. Doctors will monitor blood levels of the medicine and check for any health issues. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new drug.

Participants with liver problems can continue their regular treatment for their liver condition, but they cannot start new treatments or make major changes to their current medications shortly before the trial. Minor adjustments are allowed if the condition is stable.

Research shows that BI 3000202 is being tested for tolerability in both healthy individuals and those with liver issues. Earlier studies reported changes in blood pressure and a risk of infections in some participants. However, these side effects depended on the researchers' judgment and varied among individuals.

Unlike the standard treatments for liver disease, which often include medications like ursodeoxycholic acid or corticosteroids, BI 3000202 offers a fresh approach by potentially targeting the disease at a cellular level. This treatment is particularly exciting because it may offer benefits across different severities of liver impairment, ranging from mild to severe, something current therapies struggle with. Researchers are also enthusiastic about its potential to improve liver function more effectively, which could lead to better overall outcomes for patients.

Research is investigating BI 3000202 as a potential treatment for liver conditions. Although its effectiveness for liver disease is still under study, research in other health issues, such as systemic lupus erythematosus (SLE), has shown it might be beneficial. This medication targets specific pathways in the body, potentially reducing inflammation or related symptoms. In this trial, participants are grouped based on liver function, including mild, moderate, and severe hepatic impairment, as well as normal hepatic function. Early studies focus on understanding how the drug is absorbed and processed in individuals with these varying liver functions. This information is crucial for determining safe and effective doses for future trials.¹³⁴⁵⁶